It's a positive from me. I'll be interested to see the cash balance and hopefully the cash burn is reduced and they have another 6-12 months to improve the retail marketing. At least there is some monetary value attached albeit by a stake in the company. I interpret another avenue outside waiting for a big pharma to buy/invest in the current DEP candidates. I'll await the May webinar which will be enlightening to see how much Cheryl has diverged from previous Management and strategy. Small mercies.
Ann: Starpharma and Medicxi Partnership Petalion Therapeutics, page-22
-
- There are more pages in this discussion • 140 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
